ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,223.98
-0.44%
Dow Jones
42,732.13
0.80%
Gold vs US Dollar
2,640.60
0.00%
Brent Oil
76.495
0.00%
Bitcoin
98,406.05
0.31%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Bristol Myers Squibb Co (BMY)

  7. Bristol Myers Squibb Co (BMY) News

Bristol Myers Squibb (BMY)

Bristol Myers Squibb Co
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:BMY
DateTimeSourceHeadlineSymbolCompany
03/01/202511:59Business WireBristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare ConferenceNYSE:BMYBristol Myers Squibb Co
27/12/202422:37Business WireU.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2NYSE:BMYBristol Myers Squibb Co
23/12/202411:59Business WireBristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic ArthritisNYSE:BMYBristol Myers Squibb Co
23/12/202411:45Business WireBristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal CancerNYSE:BMYBristol Myers Squibb Co
19/12/202411:59Business WireBristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025NYSE:BMYBristol Myers Squibb Co
11/12/202421:17Business WireBristol Myers Squibb Announces Dividend IncreaseNYSE:BMYBristol Myers Squibb Co
09/12/202422:45Business WireBristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding PipelineNYSE:BMYBristol Myers Squibb Co
26/11/202411:59Business WireBristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare ConferenceNYSE:BMYBristol Myers Squibb Co
19/11/202411:59Business WireBristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research PlatformsNYSE:BMYBristol Myers Squibb Co
15/11/202413:23Business WireBristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal CancerNYSE:BMYBristol Myers Squibb Co
15/11/202411:59Business WireBristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid TumorsNYSE:BMYBristol Myers Squibb Co
12/11/202421:05GlobeNewswire Inc.Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 ResultsNYSE:BMYBristol Myers Squibb Co
11/11/202411:59Business WireBristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024NYSE:BMYBristol Myers Squibb Co
05/11/202422:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BMYBristol Myers Squibb Co
05/11/202422:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BMYBristol Myers Squibb Co
05/11/202422:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BMYBristol Myers Squibb Co
05/11/202422:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BMYBristol Myers Squibb Co
05/11/202422:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BMYBristol Myers Squibb Co
05/11/202422:00Business WireBristol Myers Squibb to Participate in Upcoming Investor ConferencesNYSE:BMYBristol Myers Squibb Co
31/10/202420:16Business WireBristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024NYSE:BMYBristol Myers Squibb Co
31/10/202410:59Business WireBristol Myers Squibb Reports Third Quarter Financial Results for 2024NYSE:BMYBristol Myers Squibb Co
28/10/202410:59Business WireBristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024NYSE:BMYBristol Myers Squibb Co
03/10/202421:35Business WireU.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)NYSE:BMYBristol Myers Squibb Co
30/09/202411:00GlobeNewswire Inc.Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell TherapiesNYSE:BMYBristol Myers Squibb Co
27/09/202423:38Business WireU.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in AdultsNYSE:BMYBristol Myers Squibb Co
27/09/202415:06Business WireBristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World SettingNYSE:BMYBristol Myers Squibb Co
27/09/202401:05Business WireU.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in AdultsNYSE:BMYBristol Myers Squibb Co
18/09/202410:59Business WireNew Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple SclerosisNYSE:BMYBristol Myers Squibb Co
15/09/202412:55Business WireBristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced MelanomaNYSE:BMYBristol Myers Squibb Co
12/09/202410:59Business WireBristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024NYSE:BMYBristol Myers Squibb Co
 Showing the most relevant articles for your search:NYSE:BMY

Your Recent History

BIT
NSCIT2678745
Assicurazioni Generali
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads